Eli Lilly Acquires Merida Biosciences for $2.87B

In a strategic move to broaden its therapeutic reach beyond metabolic disorders, Eli Lilly has agreed to acquire Merida Biosciences for up to $2.87 billion. This significant transaction, anticipated to close in the fourth quarter of 2023, signals Eli Lilly's aggressive expansion into the complex fields of allergic and autoimmune diseases.

Merida Biosciences, a relatively young company founded in 2022, has rapidly established a niche focus on developing novel treatments for conditions such as Graves' disease and thyroid eye disease. These autoimmune disorders affect millions globally, and Merida's innovative approach targets the underlying autoantibodies responsible for disease progression. The company had previously secured substantial backing, raising $121 million in April 2025 from prominent investors including Bain Capital Life Sciences, Biotechnology Value Fund, and Third Rock Ventures.

The acquisition aligns with Eli Lilly's stated objective to invest in cutting-edge biotechnology and develop therapies that fundamentally alter disease trajectories. As Francisco Ramirez-Valle, Senior Vice President of Immunology Research and Early Clinical Development at Eli Lilly, noted, the acquired company's lead program is designed to selectively neutralize disease-causing autoantibodies while preserving normal immune function. Early Phase 1 data suggests a promising profile for both efficacy and safety, with potential applications across a spectrum of antibody-mediated conditions.

This move underscores Eli Lilly's robust financial capacity, fueled by its success in the lucrative obesity and diabetes markets with blockbuster drugs like Mounjaro. The company has demonstrated a consistent appetite for strategic acquisitions, having reportedly invested approximately $28.8 billion in M&A activities in 2026 alone. Notable prior acquisitions include Centessa Pharmaceuticals, focused on sleep disorder treatments, and Kelonia Therapeutics, specializing in oncology. More recently, in July, Eli Lilly finalized a $3.8 billion deal for AtaiBeckley, a biotechnology firm backed by Peter Thiel, which is developing synthetic compounds for treatment-resistant depression.

The market for autoimmune and allergic disease treatments is substantial and growing, driven by increasing disease prevalence and a demand for more targeted and effective therapies. Graves' disease, for instance, impacts roughly 3 million individuals in the U.S., carrying significant cardiovascular and mortality risks. Furthermore, a considerable percentage of these patients develop thyroid eye disease, which can lead to vision impairment. Merida's pipeline also includes MER769, a preclinical asset targeting various allergic conditions like food allergies and asthma, alongside early-stage programs for renal and other autoimmune ailments.

Adam Townsend, CEO of Merida Biosciences, expressed enthusiasm for the integration, stating that becoming part of Eli Lilly provides the necessary resources and commitment to fully realize their scientific potential for patients. This acquisition is expected to significantly enhance Eli Lilly's presence in the immunology space, complementing its existing strengths and positioning it for future growth in a highly competitive pharmaceutical sector.